NCT06536946

Brief Summary

Examine the role of B-catenin in differentiation of cutaneous squamous cell carcinoma from other lesions that may be similar to it

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 31, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 5, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

August 6, 2024

Status Verified

August 1, 2024

Enrollment Period

7 months

First QC Date

July 31, 2024

Last Update Submit

August 3, 2024

Conditions

Cutaneous Squamous Cell Carcinoma

Keywords

B-cateninCutaneous squamous cell carcinomaImmunohistochemistry

Outcome Measures

Primary Outcomes (1)

  • Detection of B-catenin expression in cutanous squamous cell carcinoma and its mimickers

    Detection of expression of B-catenin in cutaneous squamous cell carcinoma and its mimickers by immunohistochemical procedures using antihuman B-catenin monoclonal antibodies

    6 month

Study Arms (1)

Participants

50 formalin fixed parrafin embedded tissue blocks of cutaneous squamous cell carcinoma and its mimickers , from each block 2 tissue section; one tissue section stained by Hematoxilin and Eoisin and other tissue section will be stained immunohistochemically by anti human B-catenin

Biological: Immunohistochemical staining

Interventions

Immunohistochemical stainingBIOLOGICAL

Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures

Participants

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

archived formalin fixed parrafin embedded tissue pieces of patients of cutanous squamous cell carcinoma and its mimickers admitted to sohag University hospital from period juniory 2023 to June 2024

You may qualify if:

  • tissue blocks with sufficient materials Cases with sufficient data

You may not qualify if:

  • tissue blocks with insufficient and necrotic materials. Casas with insufficient data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University hospital

Sohag, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

50 formalin fixed parrafin embedded

Central Study Contacts

Nermeen S Habeeb, Doctor

CONTACT

01200496394nermin.tharwat@med.sohag.edu.eg

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Teaching assistant of pathology

Study Record Dates

First Submitted

July 31, 2024

First Posted

August 5, 2024

Study Start

June 1, 2024

Primary Completion

December 30, 2024

Study Completion

September 30, 2025

Last Updated

August 6, 2024

Record last verified: 2024-08

Locations

EG(1)